论文部分内容阅读
为了探讨α -干扰素 +心肝宝治疗慢性乙型肝炎的疗效。材料和方法 ,对 1994年 2月～ 1998年 6月我院收治和门诊患者 5 4例 ,随机分成两组。治疗组 2 4例 ,男 18例 ,女 6例 ,平均年龄 37 7岁 ;对照组 30例 ,男 2 2例 ,女 8例 ,平均年龄 31 6岁。各组均检测肝功能 +乙肝系列 ,治疗组用较小剂量的α 2b干扰素 10 0万u ,肌注 ,每日一次 ,同时服心肝宝 6粒 ,一日三次 ,均连用 3个月。对照组用华蟾素每次 4ml,肌注 ,每日一次 ,连用 3个月。结果治疗组抗 -HBcIgM转阴占 5 0 % ,HBeAg转阴占 72 2 % (13/ 18) ,pre s2 转阴占 6 0 % (12 / 2 0 ) ,对照组相应指标为6 0 % ,6 0 % ,47 82 % ,经统计学处理仅HBeAgP <0 0 5。结论 :中小剂量α 2b干扰素 +心肝宝HBeAg转阴率优与对照组。
In order to investigate the efficacy of α - interferon + Xinganbao in the treatment of chronic hepatitis B. Materials and Methods: 54 patients admitted to our hospital and outpatients from February 1994 to June 1998 were randomly divided into two groups. Treatment group, 24 cases, 18 males and 6 females, average age 377 years; control group of 30 patients, 22 males and 8 females, mean age 31.6 years. Each group were detected liver function + hepatitis B series, the treatment group with a lower dose of α 2b interferon 10 million u, intramuscularly, once daily, while taking heart Xinbao 6, three times a day, were used in combination for 3 months. Control group with cinobufacin 4ml, intramuscular injection, once daily, once every 3 months. Results The anti-HBc IgG in the treatment group was 50% negative, HBeAg negative was 72.2% (13/18), pre s2 negative was 60% (12/20), and the control group was 60% 6 0%, 47 82%, only HBeAgP <0 0 5 after statistical treatment. CONCLUSION: The HBeAg negative rate of middle and small dose of interferon alfa + XHBD is better than that of the control group.